Allen Mooney & Barnes Investment Advisors LLC Buys 499 Shares of The Clorox Company (NYSE:CLX)

Allen Mooney & Barnes Investment Advisors LLC increased its stake in The Clorox Company (NYSE:CLXFree Report) by 11.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,776 shares of the company’s stock after buying an additional 499 shares during the quarter. Allen Mooney & Barnes Investment Advisors LLC’s holdings in Clorox were worth $681,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Tyler Stone Wealth Management bought a new stake in Clorox in the second quarter worth $25,000. Fortitude Family Office LLC bought a new stake in shares of Clorox during the fourth quarter worth $29,000. American National Bank lifted its position in shares of Clorox by 2,466.7% during the third quarter. American National Bank now owns 231 shares of the company’s stock worth $30,000 after purchasing an additional 222 shares during the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in shares of Clorox during the first quarter worth $31,000. Finally, First Capital Advisors Group LLC. bought a new stake in shares of Clorox during the second quarter worth $35,000. 78.53% of the stock is currently owned by institutional investors.

Clorox Price Performance

Shares of CLX stock opened at $151.61 on Tuesday. The Clorox Company has a fifty-two week low of $114.68 and a fifty-two week high of $178.21. The firm has a market capitalization of $18.82 billion, a price-to-earnings ratio of 240.65, a PEG ratio of 2.39 and a beta of 0.43. The company has a debt-to-equity ratio of 11.37, a quick ratio of 0.57 and a current ratio of 0.89. The stock’s 50-day simple moving average is $151.11 and its 200-day simple moving average is $140.91.

Clorox (NYSE:CLXGet Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $2.16 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $1.08. Clorox had a return on equity of 319.41% and a net margin of 1.09%. The business had revenue of $1.99 billion for the quarter, compared to analyst estimates of $1.80 billion. During the same quarter in the previous year, the firm earned $0.98 earnings per share. The company’s revenue was up 16.0% on a year-over-year basis. As a group, equities analysts forecast that The Clorox Company will post 5.51 earnings per share for the current fiscal year.

Clorox Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Stockholders of record on Wednesday, April 24th will be paid a dividend of $1.20 per share. The ex-dividend date is Tuesday, April 23rd. This represents a $4.80 dividend on an annualized basis and a dividend yield of 3.17%. Clorox’s payout ratio is 761.92%.

Analyst Upgrades and Downgrades

CLX has been the subject of several research analyst reports. Bank of America upgraded Clorox from an “underperform” rating to a “neutral” rating and lifted their target price for the stock from $120.00 to $150.00 in a research report on Friday, December 15th. Morgan Stanley reiterated an “equal weight” rating and set a $160.00 target price on shares of Clorox in a research report on Tuesday, March 26th. Barclays raised their price target on Clorox from $115.00 to $118.00 and gave the company an “underweight” rating in a research note on Tuesday, January 16th. JPMorgan Chase & Co. raised their price target on Clorox from $145.00 to $152.00 and gave the company a “neutral” rating in a research note on Thursday, January 18th. Finally, The Goldman Sachs Group initiated coverage on Clorox in a research note on Friday, March 1st. They set a “sell” rating and a $140.00 price target on the stock. Four investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and one has assigned a buy rating to the company. According to data from, the company currently has an average rating of “Hold” and an average target price of $147.06.

View Our Latest Analysis on CLX

Clorox Company Profile

(Free Report)

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Further Reading

Institutional Ownership by Quarter for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with's FREE daily email newsletter.